Bio News
AstraZeneca and Ionis said eplontersen failed to statistically significantly reduce the risk of cardiovascular events and death compared with placebo in the CARDIO-TTRansform study of more than 1,400 patients with TTR cardiomyopathy. The event rate was 29% in the eplontersen group, not substantially different from 32% in the placebo group, while 81% of patients used a stabilizer, the standard treatment. Jefferies raised the possibility that the additional benefit of combining a silencer with a stabilizer may be smaller than previously assumed, while Alnylam analyzed that it could adjust the clinical design of its next-generation candidate nucresiran.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
